G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.4 GBX -2.04% Market Closed
Market Cap: 13m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genedrive PLC
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Total Liabilities & Equity
ÂŁ3.4m
CAGR 3-Years
-20%
CAGR 5-Years
-18%
CAGR 10-Years
-13%
Oxford Nanopore Technologies PLC
LSE:ONT
Total Liabilities & Equity
ÂŁ777.1m
CAGR 3-Years
40%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Liabilities & Equity
ÂŁ35.2m
CAGR 3-Years
-7%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Total Liabilities & Equity
ÂŁ133.5m
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Total Liabilities & Equity
ÂŁ26.2m
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Total Liabilities & Equity
ÂŁ87.7m
CAGR 3-Years
29%
CAGR 5-Years
41%
CAGR 10-Years
41%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
13m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.41 GBX
Overvaluation 83%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Total Liabilities & Equity?
Total Liabilities & Equity
3.4m GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Total Liabilities & Equity amounts to 3.4m GBP.

What is Genedrive PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-13%

Over the last year, the Total Liabilities & Equity growth was -29%. The average annual Total Liabilities & Equity growth rates for Genedrive PLC have been -20% over the past three years , -18% over the past five years , and -13% over the past ten years .

Back to Top